DOCSLIB.ORG

VA Anthem Common Core Formulary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

VA Anthem Common Core Formulary Medicaid-Approved Drug List Effective August 1, 2021 Legend In each class, drugs are listed alphabetically by either brand name or generic name. Brand name drug: Uppercase in bold type Generic drug: Lowercase in plain type AL: Age Limit Restrictions DO: Dose Optimization Program GR: Gender Restriction OTC: Over the counter medication available with a prescription. (Prescribers please indicate OTC on the prescription) PA: Prior authorization is required. Prior authorization is the process of obtaining approval of benefits before certain prescriptions are filled. QL: Quantity limits; certain prescription medications have specific quantity limits per prescription or per month. SP: Specialty Pharmacy ST: Step therapy is required. You may need to use one medication before benefits for the use of another medication can be authorized. Drug Name Reference Notes *ADHD/ANTI-NARCOLEPSY/ANTI- OBESITY/ANOREXIANTS* *ADHD AGENT - SELECTIVE ALPHA ADRENERGIC AGONISTS*** clonidine hcl er oral tablet extended release Kapvay 12 hour guanfacine hcl er oral tablet extended Intuniv AL release 24 hour INTUNIV ORAL TABLET EXTENDED PA; AL RELEASE 24 HOUR KAPVAY ORAL TABLET EXTENDED PA RELEASE 12 HOUR *ADHD AGENT - SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR*** atomoxetine hcl oral capsule Strattera AL; QL QELBREE ORAL CAPSULE EXTENDED PA; DO; QL RELEASE 24 HOUR 100 MG QELBREE ORAL CAPSULE EXTENDED PA; QL RELEASE 24 HOUR 150 MG, 200 MG STRATTERA ORAL CAPSULE PA; AL; QL *AMPHETAMINE MIXTURES*** ADDERALL ORAL TABLET PA; AL ADDERALL XR ORAL CAPSULE PA; AL EXTENDED RELEASE 24 HOUR amphetamine-dextroamphet er oral capsule Adderall XR PA; AL extended release 24 hour amphetamine-dextroamphetamine oral Adderall AL tablet MYDAYIS ORAL CAPSULE EXTENDED PA; AL RELEASE 24 HOUR *AMPHETAMINES*** ADZENYS ER ORAL SUSPENSION PA; AL EXTENDED RELEASE ADZENYS XR-ODT ORAL TABLET PA; AL EXTENDED RELEASE DISPERSIBLE amphetamine er oral suspension extended Adzenys ER release amphetamine sulfate oral tablet Evekeo PA; AL DESOXYN ORAL TABLET PA; AL 2 Drug Name Reference Notes DEXEDRINE ORAL CAPSULE EXTENDED PA; AL RELEASE 24 HOUR dextroamphetamine sulfate er oral capsule Dexedrine PA; AL extended release 24 hour dextroamphetamine sulfate oral solution ProCentra PA; AL dextroamphetamine sulfate oral tablet Zenzedi AL DYANAVEL XR ORAL SUSPENSION PA; AL EXTENDED RELEASE EVEKEO ODT ORAL TABLET PA DISPERSIBLE EVEKEO ORAL TABLET PA; AL methamphetamine hcl oral tablet Desoxyn PA; AL PROCENTRA ORAL SOLUTION PA; AL VYVANSE ORAL CAPSULE AL VYVANSE ORAL TABLET CHEWABLE AL ZENZEDI ORAL TABLET PA; AL *ANALEPTIC COMBINATIONS*** energy chews oral tablet chewable OTC *ANALEPTICS*** awake maximum strength oral tablet Vivarin OTC CAFCIT INTRAVENOUS SOLUTION caffeine citrate intravenous solution Cafcit caffeine citrate oral solution caffeine oral tablet Vivarin OTC cvs caffeine oral tablet Vivarin OTC DOPRAM INTRAVENOUS SOLUTION eq stay awake oral tablet Vivarin OTC eql stay awake max st oral tablet Vivarin OTC eql stay awake oral tablet Vivarin OTC gnp alert aid oral tablet Vivarin OTC hm stay awake oral tablet Vivarin OTC keep alert oral tablet Vivarin OTC sm stay awake oral tablet Vivarin OTC stay awake maximum strength oral tablet Vivarin OTC stay awake oral tablet Vivarin OTC VIVARIN ORAL TABLET OTC 3 Drug Name Reference Notes *DOPAMINE AND NOREPINEPHRINE REUPTAKE INHIBITORS (DNRIS)*** SUNOSI ORAL TABLET PA *HISTAMINE H3-RECEPTOR ANTAGONIST/INVERSE AGONISTS*** WAKIX ORAL TABLET PA; SP *LIPASE INHIBITORS*** ALLI ORAL CAPSULE PA; OTC; QL *STIMULANTS - MISC.*** ADHANSIA XR ORAL CAPSULE PA EXTENDED RELEASE 24 HOUR APTENSIO XR ORAL CAPSULE PA; AL EXTENDED RELEASE 24 HOUR armodafinil oral tablet Nuvigil PA; AL CONCERTA ORAL TABLET EXTENDED AL RELEASE COTEMPLA XR-ODT ORAL TABLET PA EXTENDED RELEASE DISPERSIBLE DAYTRANA TRANSDERMAL PATCH AL dexmethylphenidate hcl er oral capsule Focalin XR PA; AL extended release 24 hour dexmethylphenidate hcl oral tablet Focalin PA; AL FOCALIN ORAL TABLET AL FOCALIN XR ORAL CAPSULE AL EXTENDED RELEASE 24 HOUR JORNAY PM ORAL CAPSULE EXTENDED PA RELEASE 24 HOUR METHYLIN ORAL SOLUTION PA; AL methylphenidate hcl er (cd) oral capsule PA; AL extended release methylphenidate hcl er (la) oral capsule Ritalin LA PA; AL extended release 24 hour methylphenidate hcl er (xr) oral capsule Aptensio XR PA; AL extended release 24 hour methylphenidate hcl er oral tablet extended PA; AL release 10 mg, 20 mg methylphenidate hcl er oral tablet extended Concerta PA; AL release 18 mg, 27 mg, 36 mg, 54 mg methylphenidate hcl er oral tablet extended PA; AL release 24 hour 4 Drug Name Reference Notes methylphenidate hcl er oral tablet extended Relexxii PA release 72 mg methylphenidate hcl oral solution Methylin PA; AL methylphenidate hcl oral tablet Ritalin AL methylphenidate hcl oral tablet chewable PA; AL modafinil oral tablet Provigil PA; AL NUVIGIL ORAL TABLET PA; AL PROVIGIL ORAL TABLET PA; AL QUILLICHEW ER ORAL TABLET PA CHEWABLE EXTENDED RELEASE QUILLIVANT XR ORAL SUSPENSION PA RECONSTITUTED ER RELEXXII ORAL TABLET EXTENDED RELEASE RITALIN LA ORAL CAPSULE EXTENDED PA; AL RELEASE 24 HOUR RITALIN ORAL TABLET PA; AL *ALLERGENIC EXTRACTS/BIOLOGICALS MISC* *ALLERGENIC EXTRACTS*** acacia subcutaneous solution acremonium subcutaneous solution alder subcutaneous solution alternaria subcutaneous solution american beech subcutaneous solution american cockroach subcutaneous solution american elm subcutaneous solution arizona cypress subcutaneous solution aspergillus fumigatus injection solution aureobasidium pullulans injection solution aureobasidium subcutaneous solution australian pine subcutaneous solution bahia subcutaneous solution bald cypress subcutaneous solution bayberry (wax myrtle) subcutaneous solution bermuda grass injection solution bermuda grass subcutaneous solution black willow subcutaneous solution 5 Drug Name Reference Notes botrytis injection solution botrytis subcutaneous solution brome subcutaneous solution california pepper tree subcutaneous solution candida albicans extract injection solution candida albicans extract subcutaneous solution cat hair extract injection solution cat hair extract subcutaneous solution cattle epithelium subcutaneous solution cedar elm subcutaneous solution cladosporium cladosporioides injection solution cladosporium cladosporioides intradermal solution cladosporium cladosporioides subcutaneous solution cladosporium sphaerospermum subcutaneous solution cocklebur subcutaneous solution corn pollen subcutaneous solution curvularia subcutaneous solution dandelion subcutaneous solution dog epithelium subcutaneous solution dog fennel subcutaneous solution drechslera subcutaneous solution eastern cottonwood subcutaneous solution epicoccum nigrum injection solution epicoccum subcutaneous solution fire ant subcutaneous solution fusarium subcutaneous solution german cockroach subcutaneous solution goldenrod subcutaneous solution grass pollen(k-o-r-t-swt vern) injection solution GRASTEK SUBLINGUAL TABLET PA; AL; QL SUBLINGUAL hackberry subcutaneous solution 6 Drug Name Reference Notes HONEY BEE VENOM PROTEIN INJECTION SOLUTION RECONSTITUTED honey bee venom subcutaneous solution reconstituted horse epithelium subcutaneous solution johnson grass subcutaneous solution june grass pollen standardized subcutaneous solution kapok subcutaneous solution kochia subcutaneous solution lenscale subcutaneous solution meadow fescue grass pollen subcutaneous solution melaleuca subcutaneous solution mesquite subcutaneous solution mite (d. farinae) injection solution mite (d. farinae) subcutaneous solution mite (d. pteronyssinus) injection solution mite (d. pteronyssinus) subcutaneous solution mixed ragweed subcutaneous solution mixed vespid venom protein injection solution reconstituted mixed vespid venom protein subcutaneous solution reconstituted mountain cedar subcutaneous solution mouse epithelium subcutaneous solution mucor injection solution mucor intradermal solution mucor subcutaneous solution mugwort subcutaneous solution olive tree subcutaneous solution orchard grass pollen subcutaneous solution PALFORZIA (12 MG DAILY DOSE) ORAL PA; SP; QL PALFORZIA (120 MG DAILY DOSE) ORAL PA; SP; QL PALFORZIA (160 MG DAILY DOSE) ORAL PA; SP; QL PALFORZIA (20 MG DAILY DOSE) ORAL PA; SP; QL PALFORZIA (200 MG DAILY DOSE) ORAL PA; SP; QL PALFORZIA (240 MG DAILY DOSE) ORAL PA; SP; QL 7 Drug Name Reference Notes PALFORZIA (3 MG DAILY DOSE) ORAL PA; SP; QL PALFORZIA (300 MG MAINTENANCE) PA; SP; QL ORAL PACKET PALFORZIA (300 MG TITRATION) ORAL PA; SP; QL PACKET PALFORZIA (40 MG DAILY DOSE) ORAL PA; SP; QL PALFORZIA (6 MG DAILY DOSE) ORAL PA; SP; QL PALFORZIA (80 MG DAILY DOSE) ORAL PA; SP; QL PALFORZIA INITIAL ESCALATION ORAL PA; SP; QL penicillium notatum injection solution penicillium notatum subcutaneous solution perennial rye grass pollen injection solution phoma exigua subcutaneous solution privet subcutaneous solution queen palm subcutaneous solution rabbit epithelium subcutaneous solution RAGWITEK SUBLINGUAL TABLET PA; AL SUBLINGUAL red maple subcutaneous solution red mulberry subcutaneous solution red top grass pollen subcutaneous solution rhizopus subcutaneous solution rough marsh elder subcutaneous solution russian thistle subcutaneous solution saccharomyces cerevisiae injection solution saccharomyces cerevisiae subcutaneous solution shagbark hickory subcutaneous solution sheep sorrel subcutaneous solution short ragweed pollen ext subcutaneous solution spiny pigweed subcutaneous solution stemphylium subcutaneous solution sweet gum subcutaneous
Recommended publications
  • Pharmaceutical Sciences

    Pharmaceutical Sciences

    IAJPS 2017, 4 (08), 2671 - 2680 V.L.Sravani et al ISSN 2349 - 7750 CODEN [USA]: IAJPBB ISSN: 2349 - 7750 I N D O A M E R I C A N J O U R N A L O F P H A R M A C E U T I C A L S C I E N C E S Available online at: http://www.iajps.com Research Article ANTI - ACNE ACTIVITY OF LIPIDO - STEROLIC EXTRACT OF SERENOA REPENS AND HYDRO - ALCOHOLIC EXTRACT OF GLYCYRRHIZA GLABRA IN SYRIAN HAMSTER EAR MODEL V. Laxmi Sravani 1 *, Dr. B. Ch a n drasekhar Rao 1 , Dr. D. Ravi Krishna Babu 2 1 Department of Pharma cology, RGR Siddhanthi College of Pharmacy , Secundera bad. 2 Aurigene Discovery Technologies Pvt Ltd. Miyapur, Hyderabad. Abstract : Acne vulgaris is the most commonly encountered dermatological disease of pilosebaceous unit. Androgens, which increase during puberty, stimulate the sebaceous gland to produce sebum and cause retention of keratinocytes around the sebaceous hair follicle orifice causing partial to complete blockage and leading to colonization with Propionibacterium acnes, which participates in the production of pro inflammatory mediators. For treatment of acne one of the approaches is to reduce sebum production, the main stimulus to acne; then all other pathogenic factors will diminish. A comprehensive approach combining the natural medicine with anti - androgenic activity would be fruitful area for anti - acne therapy. In this context the well documented anti - androgenic herbs like liquorice and saw palmetto were selected and screened in Syrian hamster ear model using spironolactone as standard.
  • Updates in Pediatric Dermatology

    Updates in Pediatric Dermatology

    Peds Derm Updates ELIZABETH ( LISA) SWANSON , M D ADVANCED DERMATOLOGY COLORADO ROCKY MOUNTAIN HOSPITAL FOR CHILDREN [email protected] Disclosures Speaker Sanofi Regeneron Amgen Almirall Pfizer Advisory Board Janssen Powerpoints are the peacocks of the business world; all show, no meat. — Dwight Schrute, The Office What’s New In Atopic Dermatitis? Impact of Atopic Dermatitis Eczema causes stress, sleeplessness, discomfort and worry for the entire family Treating one patient with eczema is an example of “trickle down” healthcare Patients with eczema have increased risk of: ADHD Anxiety and Depression Suicidal Ideation Parental depression Osteoporosis and osteopenia (due to steroids, decreased exercise, and chronic inflammation) Impact of Atopic Dermatitis Sleep disturbances are a really big deal Parents of kids with atopic dermatitis lose an average of 1-1.5 hours of sleep a night Even when they sleep, kids with atopic dermatitis don’t get good sleep Don’t enter REM as much or as long Growth hormone is secreted in REM (JAAD Feb 2018) Atopic Dermatitis and Food Allergies Growing evidence that food allergies might actually be caused by atopic dermatitis Impaired barrier allows food proteins to abnormally enter the body and stimulate allergy Avoiding foods can be harmful Proper nutrition is important Avoidance now linked to increased risk for allergy and anaphylaxis Refer severe eczema patients to Allergist before 4-6 mos of age to talk about food introduction Pathogenesis of Atopic Dermatitis Skin barrier
  • Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, Or Psoriasis: a Review of Clinical and Cost- Effectiveness

    Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, Or Psoriasis: a Review of Clinical and Cost- Effectiveness

    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost- Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: September 25, 2017 Report Length: 19 Pages Authors: Raywat Deonandan, Melissa Severn Cite As: Pimecrolimus for the treatment of adults with atopic dermatitis, seborrheic dermatitis, or psoriasis: a review of clinical and cost- effectiveness. Ottawa: CADTH; 2017 Sep. (CADTH rapid response report: summary with critical appraisal). Acknowledgments: ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
  • THE BARRON REPORT Volume 7, Issue 6 © 1999, Jon Barron

    THE BARRON REPORT Volume 7, Issue 6 © 1999, Jon Barron

    THE BARRON REPORT Volume 7, Issue 6 © 1999, Jon Barron. All Rights Reserved. Health For Every Man Over 30 The Prostate Problem Like women, men too are exposed to the effects of chemical estrogens in their environment. In addition, as their testosterone levels drop with age, there is, in many cases, a concomitant rise in estradiol levels -- the major reason that many older men develop breasts. Just as with women, estradiol stimulates cell growth in men too and is potentially cancerous. Estradiol stimulates the BCL2 gene, which is the gene responsible for stopping cell death. What at first glance sounds like a positive, is, upon closer inspection, not. When cell death in prostate tissue, for example, is blocked, cell growth continues unabated -- becoming a major contributing factor in the enlargement of the prostate and the development of prostate cancer. This is one of the main factors involved in the dramatically increased incidence of prostate cancer. • A new case of Prostate Cancer is diagnosed every 3 minutes in America and every 15 minutes a man dies from prostate cancer. • Prostate Cancer is the second leading type of cancer among men. • 11 million men have some form of Prostate Cancer in the United States. • African-American men have the highest rate of Prostate Cancer in the world. • Survival rates for men with prostate cancer in 1995 were no different than they were in 1965. • The age at which Prostate Cancer develops will drop ten years by the year 2000. By the year 2000, Prostate Cancer will increase by 90%. The Prostate Solution Regular use of a men's progesterone crememakes a great deal of sense for any man over the age of 30.
  • Aetna Formulary Exclusions Drug List

    Aetna Formulary Exclusions Drug List

    Covered and non-covered drugs Drugs not covered – and their covered alternatives 2020 Advanced Control Plan – Aetna Formulary Exclusions Drug List 05.03.525.1B (7/20) Below is a list of medications that will not be covered without a Key prior authorization for medical necessity. If you continue using one of these drugs without prior approval, you may be required UPPERCASE Brand-name medicine to pay the full cost. Ask your doctor to choose one of the generic lowercase italics Generic medicine or brand formulary options listed below. Preferred Options For Excluded Medications1 Excluded drug name(s) Preferred option(s) ABILIFY aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, VRAYLAR ABSORICA isotretinoin ACANYA adapalene, benzoyl peroxide, clindamycin gel (except NDC^ 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, EPIDUO, ONEXTON, TAZORAC ACIPHEX, esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT ACIPHEX SPRINKLE ACTICLATE doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg [NDC^ 72143021160 only], 75 mg, 150 mg), minocycline, tetracycline ACTOS pioglitazone ACUVAIL bromfenac, diclofenac, ketorolac, PROLENSA acyclovir cream acyclovir (except acyclovir cream), valacyclovir ADCIRCA sildenafil, tadalafil ADZENYS XR-ODT amphetamine-dextroamphetamine mixed salts ext-rel†, dexmethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel†, MYDAYIS,

  • Pimecrolimus Cream 1% PI

    Mat# 238328-01 Filename: 238328-01_PimecroCrm30gPi_5_18.indd Proof# 1 Artist Name/Date: Mike Aspinall 9/10/18 AMT Version: 10 Sep 2018 Vault# VV-141752 Approvals:* NDA/ANDA# 209345 Black Approval: Date: Approval: Date: ” n/a Rev: * Applicable when approver is not able to apply electronic signature to PDF in Veeva Vault or Acrobat® Electronic and scanned proxy approval signatures appear on separate pages following the proof pages within this PDF Iss. 5/2018 n/a Created by: Outsert Configuration: Regulatory Affairs US Artwork Management Team Flat: 10” x 27” 1070 Horsham Road, North Wales, PA, 19454 Phone 215-591-3000 Fold: 5” x 2.25” Die Line - No Print 10” 10.00 1/8” 5” 5” 2.25” .25” 238328-01 238328-01 Pimecrolimus Cream Pimecrolimus Cream Rx only Rx only 238328-01 238328-01 Iss. 5/2018 Iss. 5/2018 HIGHLIGHTS OF PRESCRIBING INFORMATION • If signs and symptoms persist beyond 6 weeks, patients should be 8 USE IN SPECIFIC POPULATIONS These highlights do not include all the information needed to use re-examined. (2) 8.1 Pregnancy PIMECROLIMUS CREAM safely and effectively. See full prescribing • Continuous long-term use of pimecrolimus cream, 1% should be Pregnancy Category C information for PIMECROLIMUS CREAM. avoided. (2) There are no adequate and well-controlled studies with pimecrolimus cream, 1% in pregnant women. Therefore, pimecrolimus cream, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. PIMECROLIMUS cream, 1% for topical use • Avoid use with occlusive dressings. (2) Initial U.S. Approval: 2001 In dermal embryofetal developmental studies, no maternal or fetal toxicity was observed up to the highest practicable doses tested, 10 mg/kg/day DOSAGE FORMS AND STRENGTHS ”2 (1% pimecrolimus cream) in rats (0.14X MRHD based on body surface area) and 10 mg/kg/day (1% pimecrolimus cream) in rabbits (0.65X MRHD WARNING: LONG-TERM SAFETY OF TOPICAL CALCINEURIN Cream, 1%.
  • Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
  • Merck & Co., Inc

    Merck & Co., Inc

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 1-6571 Merck & Co., Inc. One Merck Drive Whitehouse Station, N.J. 08889-0100 (908) 423-1000 Incorporated in New Jersey I.R.S. Employer Identification No. 22-1918501 The number of shares of common stock outstanding as of the close of business on October 31, 2013: 2,921,928,875 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
  • The 5ARI Withdrawal Syndrome (5ARI-WS)

    The 5ARI Withdrawal Syndrome (5ARI-WS)

    The 5ARI Withdrawal Syndrome (5ARI-WS) The Silenced Androgen Receptor (AR) Theory: Explaining persistent side effects arising from 5alpha reductase (5AR) inhibitor (5ARI) use By “Awor” and “Mew”, Administrators of Propeciahelp.com (July 2010) 1. Introduction An increasingly overwhelming amount of evidence is starting to accumulate from various doctors, scientists, patient groups and online discussion forums, whereby seemingly unrelated substances such as finasteride, dutasteride, isotretinoin and saw palmetto extract (SPE) based preparations are causing young consumers to suffer from long-term, irreversible and serious health damage. The experienced persistent side effect have a clear denominator in that they all seem to relate to physiological and psychological functions which require androgens to function correctly: Loss of libido (1) (2) Low energy, fatigue (1) Depression (including suicidal depression)* (3) (4) (5) (6) Impaired thought processes* (7) Memory failure* (7) Erectile dysfunction (8) (9) (2) Penile atrophy (9) Impaired spermatogenesis (10) (11) (12) Muscle wasting (13) (14) (15) Gynecomastia (16) Dry skin and dry eyes (17) (18) (19) Prostate problems (2) Metabolic syndrome (20) Osteoporosis (21) (22) Anxiety and sleep disorders, muscle spasms (23) (24) (25) * Indirect action through 3α-HSD as described later in this document Of substantial note is that most side effects typically surface or reach full extent roughly 10-14 days after quitting the 5ARI substances. Androgen dependent tissue atrophy (penile, scrotum,
  • Schering-Plough 2003 Annual Report

    Schering-Plough 2003 Annual Report

    Schering-Plough 2003 Annual Report To earn trust, every day. Schering-Plough 2003 Annual Report Schering-Plough is a global pharmaceutical company with leading prescription, consumer and animal health products. The Company began a fundamental transformation under new leadership in 2003, changing from a decentralized holding company to a centralized global operation focused on meeting the needs of our customers. Today, we are building the foundation for long-term, sustainable growth, while remaining committed to business integrity, quality and compliance in everything we do. Our goal is to provide a steady flow of innovative, science-based medicines and services while earning the trust of the physicians, patients and customers we serve. Contents 1 Letter to Stakeholders 43 Consolidated Balance Sheets 4 Financial Highlights 44 Statements of Consolidated Shareholders’ Equity 5 Champions for the Doctor and Patient 45 Notes to Consolidated Financial Statements 16 An Interview with Fred Hassan 67 Report by Management 18 Business and Science Review 68 Independent Auditors’ Report 24 Key Products 69 Six-Year Selected Financial & Statistical Data 25 Management’s Discussion and Analysis 70 Quarterly Data of Operations and Financial Condition 74 Directors and Senior Management 42 Statements of Consolidated Operations 75 Corporate Information 42 Statements of Consolidated Cash Flows < Margaret van Heek, Ph.D. Scientific curiosity and basic research light the path to discovering new drugs. Dr. Margaret van Heek and her team of scientists were instrumental in determining how ZETIA, the Company’s novel cholesterol absorption inhibitor, works in vivo to lower cholesterol. At her lab in Kenilworth, N.J., she is currently researching new and better ways to help patients lower their cholesterol as well as treat diabetes and other metabolic conditions.
  • Beta-Sitosterol [BSS] and Betasitosterol Glucoside [BSSG] As an Adjuvant in the Treatment of Pulmonary Tuberculosis Patients.” TB Weekly (4 Mar 1996)

    Beta-Sitosterol [BSS] and Betasitosterol Glucoside [BSSG] As an Adjuvant in the Treatment of Pulmonary Tuberculosis Patients.” TB Weekly (4 Mar 1996)

    Saw Palmetto (Serenoa repens) and One of Its Constituent Sterols -Sitosterol [83-46-5] Review of Toxicological Literature Prepared for Errol Zeiger, Ph.D. National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, North Carolina 27709 Contract No. N01-ES-65402 Submitted by Raymond Tice, Ph.D. Integrated Laboratory Systems P.O. Box 13501 Research Triangle Park, North Carolina 27709 November 1997 EXECUTIVE SUMMARY The nomination of saw palmetto and -sitosterol for testing is based on the potential for human exposure and the limited amount of toxicity and carcinogenicity data. Saw palmetto (Serenoa repens), a member of the palm family Arecaceae, is native to the West Indies and the Atlantic Coast of North America, from South Carolina to Florida. The plant may grow to a height of 20 feet (6.10 m), with leaves up to 3 feet (0.914 m) across. The berries are fleshy, about 0.75 inch (1.9 cm) in diameter, and blue-black in color. Saw palmetto berries contain sterols and lipids, including relatively high concentrations of free and bound sitosterols. The following chemicals have been identified in the berries: anthranilic acid, capric acid, caproic acid, caprylic acid, - carotene, ferulic acid, mannitol, -sitosterol, -sitosterol-D-glucoside, linoleic acid, myristic acid, oleic acid, palmitic acid, 1-monolaurin and 1-monomyristin. A number of other common plants (e.g., basil, corn, soybean) also contain -sitosterol. Saw palmetto extract has become the sixth best-selling herbal dietary supplement in the United States. In Europe, several pharmaceutical companies sell saw palmetto-based over-the-counter (OTC) drugs for treating benign prostatic hyperplasia (BPH).